Biohaven Pharmaceutical Q3 EPS $(1.91) Beats $(2.40) Estimate, Sales $135.74M Beat $128.40M Estimate
Portfolio Pulse from Benzinga Newsdesk
Biohaven Pharmaceutical reported a Q3 EPS of $(1.91), beating the estimate of $(2.40). The company's sales reached $135.74 million, surpassing the expected $128.40 million.
November 09, 2021 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biohaven Pharmaceutical's Q3 earnings report shows a better-than-expected EPS of $(1.91) and sales of $135.74 million, both beating analyst estimates.
Biohaven's better-than-expected EPS and sales figures are likely to positively impact its stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100